CNP
62
12
MPC
63
-5
DG
40
-2
FOX
60
-2
RHI
27
2
LLY
68
4
HRB
56
2
DOV
52
2
MS
59
-2
MAC
47
4
KMB
42
2
NRG
55
-4
F
40
-6
EQT
54
4
DHI
52
2
CINF
41
4
PHM
46
3
TSN
42
2
WHR
57
-5
MRK
45
2
CNP
62
12
MPC
63
-5
DG
40
-2
FOX
60
-2
RHI
27
2
LLY
68
4
HRB
56
2
DOV
52
2
MS
59
-2
MAC
47
4
KMB
42
2
NRG
55
-4
F
40
-6
EQT
54
4
DHI
52
2
CINF
41
4
PHM
46
3
TSN
42
2
WHR
57
-5
MRK
45
2
Financhill
Back

Cyclacel Pharmaceuticals 10K Form

Sell
33

CYCC
Cyclacel Pharmaceuticals

Last Price:
$8.26
Seasonality Move:
-9.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYCC News And Ratings

See the #1 stock for the next 7 days that we like better than CYCC

CYCC Financial Statistics

Sales & Book Value

Annual Sales: $43K
Cash Flow: $-3.2M
Price / Cash Flow: 0
Annual Sales: $0.24
Price / Book: 4.24

Profitability

EPS (TTM): -19.68000
Net Income (TTM): $-8.3M
Gross Margin: $1.9M
Return on Equity: -2462.6%
Return on Assets: -163.64%

Cyclacel Pharmaceuticals Earnings Forecast

Key Cyclacel Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 18 years for CYCC is 97.74%.
  • The Selling, General & Administrative Expenses for CYCC have been equal to 12,539.53% of Gross Profit Margin.
  • The Research & Development expenses have been 15,476.74% of Revenue.
  • The Net Earning history of CYCC is -26,074.42% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 21 years.

Cyclacel Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYCC
CUSIP: 23254L
Website: cyclacel.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0.77
Quick Ratio: 0.72

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYCC Technical Analysis vs Fundamental Analysis

Sell
33
Cyclacel Pharmaceuticals (CYCC) is a Sell

Is Cyclacel Pharmaceuticals a Buy or a Sell?